Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis

Neurobiology of Disease

Volumn 46, Issue 3, 2012, Pages 572-580

  Jain, Samay ^a   Goldstein, David S ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autonomic dysfunction; Catecholamine; Dysautonomia; Neurodegeneration; Non motor features; Orthostasis; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; CATECHOLAMINE; DOPAMINE;

AUTONOMIC DYSFUNCTION; BALANCE DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DYSAUTONOMIA; CATALYSIS; CATECHOLAMINE NERVE CELL; CATECHOLAMINE UPTAKE; CLINICAL FEATURE; CYTOPLASM; DENERVATION; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; HEART INNERVATION; HUMAN; LABORATORY TEST; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROIMAGING; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; ORTHOSTATIC HYPOTENSION; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEPLETION; REVIEW; SHY DRAGER SYNDROME; STANDING; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; TREMOR;

AUTONOMIC NERVOUS SYSTEM; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CATECHOLAMINES; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; HUMANS; PARKINSON DISEASE; PRIMARY DYSAUTONOMIAS; SYMPATHECTOMY;

EID: 84860823589     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.10.025     Document Type: Review

References (52)

1. Amino T., et al. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Path. 2005, 15:29-34.
2. Braak H., et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 2003, 110:517-536.
3. Braak H., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
4. Burke W.J., et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008, 115:193-203.
5. Caudle W.M., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007, 27:8138-8148.
6. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2003, 2:669-676.
7. Goldstein D.S. Orthostatic hypotension as an early finding in Parkinson disease. Clin. Auton. Res. 2006, 16:46-64.
8. Goldstein D.S., Orimo S. Cardiac sympathetic neuroimaging: summary of the First International Symposium. Clin. Auton. Res. 2009, 19:133-136.
9. Goldstein D.S., Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation 2009, 119:139-146.
10. Goldstein D.S., Tack C. Non-invasive detection of sympathetic neurocirculatory failure. Clin. Auton. Res. 2000, 10:285-291.
11. Goldstein D.S., et al. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J. Clin. Invest. 1988, 81:213-220.
12. Goldstein D.S., et al. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 1997, 336:696-702.
13. Goldstein D.S., et al. Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clin. Auton. Res. 2002, 12:281-285.
14. Goldstein D.S., et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002, 58:1247-1255.
15. Goldstein D.S., et al. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology 2003, 60:1327-1332.
16. Goldstein D.S., et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 2005, 46:1333-1339.
17. Goldstein D.S., et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin. Auton. Res. 2007, 17:118-121.
18. Goldstein D.S., et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat. Disord. 2008, 14:600-607.
19. Goldstein D.S., et al. Association of anosmia with autonomic failure in Parkinson disease. Neurology 2009, 74:245-251.
20. Goldstein D.S., et al. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J. Clin. Investig. 2011, 121:3320-3330.
21. Goldstein D.S., et al. Catechols in post-mortem brain of patients with Parkinson disease. Eur. J. Neurol. 2011, 18:703-710.
22. Goldstein, D. S., et al., in press-a. Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clin. Auton. Res. doi:10.1016/j.jns.2011.04.011.
23. Goldstein, D. S., et al., in press-b. Autonomic dysfunction in PD: a window to early detection? J. Neurol. Sci. doi:10.1007/s10286-011-0136-4.
24. Imrich R., et al. Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism Relat. Disord. 2009, 15:122-127.
25. Imrich R., et al. Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab. Clin. Auton. Res. 2009, 19:259-262.
26. Jinsmaa Y., et al. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol. 2009, 22:835-841.
27. Kashihara K., et al. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16:252-255.
28. Kaufmann H., et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003, 108:724-728.
29. Lamensdorf I., et al. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J. Neurosci. Res. 2000, 60:552-558.
30. Lamensdorf I., et al. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res. 2000, 868:191-201.
31. Legros H., et al. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. J. Neurosci. Res. 2004, 75:429-435.
32. Li S.T., et al. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann. Neurol. 2002, 52:220-223.
33. Marchitti S.A., et al. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 2007, 59:125-150.
34. Mitchell I.J., et al. Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience 1994, 63:1-5.
35. Moak J.P., et al. Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Cleve. Clin. J. Med. 2009, 76(Suppl 2):S51-S59.
36. Mosharov E.V., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
37. Nanda R.N., et al. Treatment of neurogenic orthostatic hypotension with a monoamine oxidase inhibitor and tyramine. Lancet 1976, 2:1164-1167.
38. Orimo S., et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 2002, 73:776-777.
39. Orimo S., et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. (Berl.) 2007, 113:81-86.
40. Panneton W.M., et al. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 2010, 5:e15251.
41. Polinsky R.J., et al. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981, 31:1-7.
42. Rahman F., et al. Low frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Clin. Auton. Res. 2011, 21:133-141.
43. Schrezenmaier C., et al. Adrenergic and vagal baroreflex sensitivity in autonomic failure. Arch. Neurol. 2007, 64:381-386.
44. Senard J.M., et al. Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur. J. Clin. Investig. 1990, 20:613-619.
45. Senard J.M., et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson disease or multiple system atrophy. Clin. Neuropharmacol. 1993, 16:70-76.
46. Shannon J.R., et al. Sympathetically mediated hypertension in autonomic failure. Circulation 2000, 101:2710-2715.
47. Sharabi Y., et al. Neurotransmitter specificity of sympathetic denervation in Parkinson's disease. Neurology 2003, 60:1036-1039.
48. Sharabi Y., et al. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin. Neuropharmacol. 2006, 29:97-105.
49. Taylor T.N., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009, 29:8103-8113.
50. Velseboer D.C., et al. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 2011, 10.1016/j.parkreldis.2011.04.016.
51. Vernino S., et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N. Engl. J. Med. 2000, 343:847-855.
52. Yoshita M., et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006, 66:1850-1854.